Shopping Cart 0
Cart Subtotal
USD 0

Galderma SA - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Galderma SA (Galderma), a subsidiary of Nestle SA, is a pharmaceutical company that develops and markets drugs, medical dermatology solutions and therapeutic skin care products for the treatment of hair, nail, and skin diseases. Galderma offers products for the treatment of skin conditions such as seborrheic dermatitis, dry skin, acne, psoriasis, atopic dermatitis, steroid responsive dermatoses, pigmentation disorders, aging skin, onychomycosis, rosacea, skin cancer and others. The company offers products leading brands such as Azzalure, Cetaphil, Clobex, Macrolane, and Oracea among several others. It markets products in India, Greece, Italy, Canada, Chile, Poland, the UK, and the US, among others. The company operates manufacturing facilities in France, Sweden, Canada, Brazil, Germany and Switzerland and research and development (R&D) centers in France, Sweden, the US, Switzerland and Japan. Galderma is headquartered in Lausanne, Switzerland.

Galderma SA-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Galderma SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Galderma SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Galderma SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Galderma SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Galderma SA, Medical Devices Deals, 2012 to YTD 2018 9

Galderma SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Galderma SA, Pharmaceuticals & Healthcare, Deal Details 11

Asset Purchase 11

Galderma to Acquire Assets of Laboratoires Inneov from L'Oreal 11

Galderma Completes Acquisition of Aesthetic Dermatology Assets from Valeant Pharma for USD1.4 Billion 12

Galderma Acquires Pekiron Cream From Kyorin Pharma 13

Partnerships 14

Oncodesign Enters into Service Partnership with Galderma 14

Galderma Enters into Research Agreement with Icahn School of Medicine at Mount Sinai and Northwestern University Feinberg School of Medicine 15

Bioventus Enters into Agreement with Galderma for Durolane in US 16

Galderma Enters into Distribution Agreement with Ipsen for Dysport in Asia-Pacific 17

Galderma Enters into Agreement with ZELTIQ Aesthetics 18

Galderma Enters into Agreement with ImaBiotech 19

Ipsen Extends Distribution Agreement with Galderma for Dysport 20

Ipsen Extends Distribution Agreement With Galderma For Dysport 22

Sinclair IS Pharma Enters Into Co-Promotion Agreement With Galderma For Kelo-cote 23

Licensing Agreements 24

Clementia Pharma Enters into Licensing Agreement with Galderma R&D 24

Galderma Pharma Enters into Licensing Agreement with Chugai Pharma 25

Nuvo Research Enters into Licensing Agreement with Galderma Pharma for Pliaglis 26

Asset Transactions 27

Bioventus Acquires Durolane Assets From Galderma 27

Onset Dermatologics Acquires Worldwide Rights To Clindagel From Galderma Labs 28

STADA Arzneimittel Completes Acquisition Of Generics Business From Spirig Pharma For USD 108 Million 29

Acquisition 30

Nestle Completes Acquisition of Remaining 50% Stake in Galderma for USD3.5 Billion 30

Galderma Pharma Acquires Spirig Pharma 32

Galderma SA-Key Competitors 33

Galderma SA-Key Employees 34

Galderma SA-Locations And Subsidiaries 35

Head Office 35

Other Locations & Subsidiaries 35

Appendix 38

Methodology 38

About GlobalData 38

Contact Us 38

Disclaimer 38


List Of Figure

List of Figures

Galderma SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Galderma SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Galderma SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Galderma SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Galderma SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Galderma SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Galderma SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Galderma SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Galderma SA, Medical Devices Deals, 2012 to YTD 2018 9


List Of Table

List of Tables

Galderma SA, Pharmaceuticals & Healthcare, Key Facts 2

Galderma SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Galderma SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Galderma SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Galderma SA, Deals By Therapy Area, 2012 to YTD 2018 8

Galderma SA, Medical Devices Deals, 2012 to YTD 2018 9

Galderma SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Galderma to Acquire Assets of Laboratoires Inneov from L'Oreal 11

Galderma Completes Acquisition of Aesthetic Dermatology Assets from Valeant Pharma for USD1.4 Billion 12

Galderma Acquires Pekiron Cream From Kyorin Pharma 13

Oncodesign Enters into Service Partnership with Galderma 14

Galderma Enters into Research Agreement with Icahn School of Medicine at Mount Sinai and Northwestern University Feinberg School of Medicine 15

Bioventus Enters into Agreement with Galderma for Durolane in US 16

Galderma Enters into Distribution Agreement with Ipsen for Dysport in Asia-Pacific 17

Galderma Enters into Agreement with ZELTIQ Aesthetics 18

Galderma Enters into Agreement with ImaBiotech 19

Ipsen Extends Distribution Agreement with Galderma for Dysport 20

Ipsen Extends Distribution Agreement With Galderma For Dysport 22

Sinclair IS Pharma Enters Into Co-Promotion Agreement With Galderma For Kelo-cote 23

Clementia Pharma Enters into Licensing Agreement with Galderma R&D 24

Galderma Pharma Enters into Licensing Agreement with Chugai Pharma 25

Nuvo Research Enters into Licensing Agreement with Galderma Pharma for Pliaglis 26

Bioventus Acquires Durolane Assets From Galderma 27

Onset Dermatologics Acquires Worldwide Rights To Clindagel From Galderma Labs 28

STADA Arzneimittel Completes Acquisition Of Generics Business From Spirig Pharma For USD 108 Million 29

Nestle Completes Acquisition of Remaining 50% Stake in Galderma for USD3.5 Billion 30

Galderma Pharma Acquires Spirig Pharma 32

Galderma SA, Key Competitors 33

Galderma SA, Key Employees 34

Galderma SA, Other Locations 35

Galderma SA, Subsidiaries 35

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Company Profile

Company Profile Title

Summary

Galderma SA (Galderma), a subsidiary of Nestle SA, is a pharmaceutical company that develops and markets drugs, medical dermatology solutions and therapeutic skin care products for the treatment of hair, nail, and skin diseases. Galderma offers products for the treatment of skin conditions such as seborrheic dermatitis, dry skin, acne, psoriasis, atopic dermatitis, steroid responsive dermatoses, pigmentation disorders, aging skin, onychomycosis, rosacea, skin cancer and others. The company offers products leading brands such as Azzalure, Cetaphil, Clobex, Macrolane, and Oracea among several others. It markets products in India, Greece, Italy, Canada, Chile, Poland, the UK, and the US, among others. The company operates manufacturing facilities in France, Sweden, Canada, Brazil, Germany and Switzerland and research and development (R&D) centers in France, Sweden, the US, Switzerland and Japan. Galderma is headquartered in Lausanne, Switzerland.

Galderma SA-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Galderma SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Galderma SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Galderma SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Galderma SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Galderma SA, Medical Devices Deals, 2012 to YTD 2018 9

Galderma SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Galderma SA, Pharmaceuticals & Healthcare, Deal Details 11

Asset Purchase 11

Galderma to Acquire Assets of Laboratoires Inneov from L'Oreal 11

Galderma Completes Acquisition of Aesthetic Dermatology Assets from Valeant Pharma for USD1.4 Billion 12

Galderma Acquires Pekiron Cream From Kyorin Pharma 13

Partnerships 14

Oncodesign Enters into Service Partnership with Galderma 14

Galderma Enters into Research Agreement with Icahn School of Medicine at Mount Sinai and Northwestern University Feinberg School of Medicine 15

Bioventus Enters into Agreement with Galderma for Durolane in US 16

Galderma Enters into Distribution Agreement with Ipsen for Dysport in Asia-Pacific 17

Galderma Enters into Agreement with ZELTIQ Aesthetics 18

Galderma Enters into Agreement with ImaBiotech 19

Ipsen Extends Distribution Agreement with Galderma for Dysport 20

Ipsen Extends Distribution Agreement With Galderma For Dysport 22

Sinclair IS Pharma Enters Into Co-Promotion Agreement With Galderma For Kelo-cote 23

Licensing Agreements 24

Clementia Pharma Enters into Licensing Agreement with Galderma R&D 24

Galderma Pharma Enters into Licensing Agreement with Chugai Pharma 25

Nuvo Research Enters into Licensing Agreement with Galderma Pharma for Pliaglis 26

Asset Transactions 27

Bioventus Acquires Durolane Assets From Galderma 27

Onset Dermatologics Acquires Worldwide Rights To Clindagel From Galderma Labs 28

STADA Arzneimittel Completes Acquisition Of Generics Business From Spirig Pharma For USD 108 Million 29

Acquisition 30

Nestle Completes Acquisition of Remaining 50% Stake in Galderma for USD3.5 Billion 30

Galderma Pharma Acquires Spirig Pharma 32

Galderma SA-Key Competitors 33

Galderma SA-Key Employees 34

Galderma SA-Locations And Subsidiaries 35

Head Office 35

Other Locations & Subsidiaries 35

Appendix 38

Methodology 38

About GlobalData 38

Contact Us 38

Disclaimer 38


List Of Figure

List of Figures

Galderma SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Galderma SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Galderma SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Galderma SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Galderma SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Galderma SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Galderma SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Galderma SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Galderma SA, Medical Devices Deals, 2012 to YTD 2018 9


List Of Table

List of Tables

Galderma SA, Pharmaceuticals & Healthcare, Key Facts 2

Galderma SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Galderma SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Galderma SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Galderma SA, Deals By Therapy Area, 2012 to YTD 2018 8

Galderma SA, Medical Devices Deals, 2012 to YTD 2018 9

Galderma SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Galderma to Acquire Assets of Laboratoires Inneov from L'Oreal 11

Galderma Completes Acquisition of Aesthetic Dermatology Assets from Valeant Pharma for USD1.4 Billion 12

Galderma Acquires Pekiron Cream From Kyorin Pharma 13

Oncodesign Enters into Service Partnership with Galderma 14

Galderma Enters into Research Agreement with Icahn School of Medicine at Mount Sinai and Northwestern University Feinberg School of Medicine 15

Bioventus Enters into Agreement with Galderma for Durolane in US 16

Galderma Enters into Distribution Agreement with Ipsen for Dysport in Asia-Pacific 17

Galderma Enters into Agreement with ZELTIQ Aesthetics 18

Galderma Enters into Agreement with ImaBiotech 19

Ipsen Extends Distribution Agreement with Galderma for Dysport 20

Ipsen Extends Distribution Agreement With Galderma For Dysport 22

Sinclair IS Pharma Enters Into Co-Promotion Agreement With Galderma For Kelo-cote 23

Clementia Pharma Enters into Licensing Agreement with Galderma R&D 24

Galderma Pharma Enters into Licensing Agreement with Chugai Pharma 25

Nuvo Research Enters into Licensing Agreement with Galderma Pharma for Pliaglis 26

Bioventus Acquires Durolane Assets From Galderma 27

Onset Dermatologics Acquires Worldwide Rights To Clindagel From Galderma Labs 28

STADA Arzneimittel Completes Acquisition Of Generics Business From Spirig Pharma For USD 108 Million 29

Nestle Completes Acquisition of Remaining 50% Stake in Galderma for USD3.5 Billion 30

Galderma Pharma Acquires Spirig Pharma 32

Galderma SA, Key Competitors 33

Galderma SA, Key Employees 34

Galderma SA, Other Locations 35

Galderma SA, Subsidiaries 35

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS